Company intelligence / Profile preview
Alpha Biopharma
Shanghai, Shanghai, Chinaalphabiopharma.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Commercial
01
Overview
Alpha Biopharma's lead product Zorifer (zorifertinib) received NMPA approval in December 2024 for EGFR-mutated NSCLC with CNS metastases. Phase III trials demonstrated consistent benefits in patients with intracranial symptoms, EGFR L858R mutations, and multiple lesions, potentially prolonging overall survival with sequential use of zorifertinib and third-generation EGFR-TKIs.[3]
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesNK cell therapiesCAR-T cell therapies
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
AstraZenecaWugen Inc
Beyond the preview
Go deeper on Alpha Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alpha Biopharma.